Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients

NCT07075770 · tracked via the Priya Life Science Italy tracker

Sponsor

I.R.C.C.S. Fondazione Santa Lucia

Phase

Not applicable

Started

2025-01-01

Last updated

2026-01-13

Condition(s) studied

Alzheimer Disease

Investigational drug(s) / intervention(s)

Combined iTBS-tACSiTBS-sham tACSsham iTBS- sham tACS

Combined iTBS-tACS: The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. iTBS and tACS will be synchronized using a BrainTrigger and SIGNAL Software so that both stimulations will start simultaneously

iTBS-sham tACS: The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings.

sham iTBS- sham tACS: The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. For the iTBS sham condition, stimulation was delivered with the coil angled at 90°, with only the edge of the coil resting on the scalp.. For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings.

Study summary

Alzheimer's disease (AD) is increasingly recognized as a disorder marked by early synaptic dysfunction and disrupted brain network connectivity, beyond the traditional focus on amyloid pathology. Synaptic plasticity (crucial for learning and memory) is compromised in AD and represents a promising therapeutic target. In particular, alterations in the Default Mode Network (DMN), especially in regions like the precuneus, suggest that restoring connectivity and enhancing plasticity may improve cognitive outcomes. This project proposes a novel, precision-delivered non-invasive brain stimulation protocol that combines repetitive transcranial magnetic stimulation (rTMS) and transcranial alternating current stimulation (tACS) over the DMN. The intervention will be evaluated through cognitive testing, blood-based biomarkers, MRI and TMS-EEG, alongside immersive virtual environments to assess sensorimotor and cognitive function. This approach aims to test neuromodulation strategies capable of slowing neurodegeneration and supporting early detection and rehabilitation in AD.

Eligibility

Sex

ALL

Min age

50 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Patients with a diagnosis of AD according to IWG criteria * 20 \> MMSE \< 28 * Patients with CSF specific biomarker profile or with a positive Amyloid Pet Scan consistent with the presence of amyloid pathology * Global Clinical Dementia Rating (CDR) ≤1 * Previous decline in cognition for more than six months as documented in patient medical records * A caregiver available and living in the same household or interacting with the patient and available * Patients living at home or nursing home setting without continuous nursing care * General health status acceptable for a participation in a 6-month clinical trial * Stable pharmacological treatment for at least one month prior to screening * No regular intake of prohibited medications. * Signed informed consent by the patient. If there are any doubts that the patient is mentally capable of giving informed consent, the patient will be examined and verified to be mentally capable by an independent physician/ neurologist, prior to the initiation of any study specific procedure. Signed consent of the caregiver Exclusion Criteria: * Failure to undergo screening or baseline exams * Hospitalization or change in chronic concomitant medications one month before the screening or during the screening period * Clinical, laboratory, or neuroimaging results consistent with: 1. other primary degenerative dementia (Lewy body dementia, frontotemporal dementia, Huntington's disease, Creutzfeldt-Jakob disease, Down syndrome, etc.); 2. other neurodegenerative conditions (Parkinson's disease, amyotrophic lateral sclerosis, etc.); 3. orthostatic hypotension and autonomic disorders 4. cerebrovascular disease (major infarction, a strategic infarction or multiple lacunar infarctions, extensive white matter lesions \> one quarter of total white matter); 5. other central nervous system diseases (severe traumatic brain injury, tumors, subdural hematoma, or other space-occupying processes, etc.); 6. seizure disorder. 7. Other infectious, metabolic, or systemic diseases affecting the central nervous system (syphilis, existing hypothyroidism, current vitamin B12 or folate deficiency, serum electrolytes outside normal limits, juvenile diabetes, etc.). * A current DSM-V diagnosis of major depression, schizophrenia, or bipolar disorder. * Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable assessments and may affect the assessment of the patient's clinical or mental state, or expose the patient to special risk, such as: 1. Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulties, etc.); 2. Opioid-containing analgesics 3. Suspected or known drug or alcohol abuse, i.e., more than about 60 g of alcohol (about 1 liter of beer or 500 ml of wine) per day, indicated by a high mean corpuscular volume (MCV) above the normal value at screening; 4. Any condition that, in the investigator's judgment, makes the patient unsuitable for inclusion

Primary outcome measure(s)

integrated Alzheimer Disease Rating Scale (iADRS) — Change from baseline to the end of treatment at week 24.
The iADRS is an integrated assessment of cognition and daily function from the 13-item cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog13) and Alzheimer Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL), measuring global disease severity across the Alzheimer disease continuum as a single summary score. The iADRS is validated and captures clinical progression from MCI due to Alzheimer disease through moderate dementia due to Alzheimer disease, and treatment effects have been demonstrated across MCI and Alzheimer disease with mild dementia. The possible scores on the iADRS range from 0 to 144 (lower scores indicate greater impairment).

Trial sites (2)

Facility	City	Region	Status
IRCCS Santa Lucia Foundation	Rome	Italy	Recruiting
I.R.C.C.S. Centro Neurolesi Bonino Pulejo	Messina	Sicily	Not Yet Recruiting

More I.R.C.C.S. Fondazione Santa Lucia trials in Italy

Design and Validation of Innovative Strategies Based on Dual-Task Approach Active, not recruiting

Visuo-Vestibular VR-based Stimulation Effects on Balance and Gait in Stroke Survivors Recruiting

Spatiotemporal Entrainment Neuromodulation Targeting Cerebello-Cerebral Circuits to Enhance Cognitive and Social Rehabilitation in Cerebellar Diseases Recruiting

Digital Twins for Model-driven Non-invasive Electrical Brain Stimulation Active, not recruiting

Proprioceptive Exercise in Parkinson's Disease Active, not recruiting

Other trials for the same condition

The Brain&Senses Study Active, not recruiting

Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia Recruiting

A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia Recruiting

Biomarkers of Synaptic Damage in Multiple Sclerosis Recruiting

Digital Twins for Model-driven Non-invasive Electrical Brain Stimulation Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07075770 on ClinicalTrials.gov ↗ ← All trials in Italy